Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study

Chih Ping Han, Lai Fong Kok., Ming Yung Lee, Tina S. Wu, Alexandra Ruan, Ya Wen Cheng, Po Hui Wang, Chiew Loon Koo, Yeu Sheng Tyan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor's site of origin. Some panels of antibodies help to distinguish primary ECA from EMA. However, unexpected expressions of those markers often exist, which causes this diagnostic dilemma to be still unresolved. In this study, we investigate Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) to evaluate their potential use in distinguishing between these two gynecologic malignancies. Methods A tissue microarray was constructed using paraYnembedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. Utilizing the avidin-biotin (ABC) technique, tissue array sections were immunostained with the Wve aforementioned commercially available antibodies. Results Immunohistochemical (IHC) expressions of p53, TTF1, CK7, CK20, and CK34βE12 were all nonsignificant (P > 0.05) in frequency diVerences between the immunostaining results (positive vs. negative) in tumors from both the two primary adenocarcinomas (ECA vs. EMA). Conclusion It is still uncertain which markers or panels would be the most appropriate for making diagnoses; hence, exploration of other useful markers, which make a deWnitive distinction between ECA and EMA merits further studies. This study, however, uncovered that the Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) are of no beneWcial value in distinguishing between primary ECA and EMA.

Original languageEnglish
Pages (from-to)317-323
Number of pages7
JournalArchives of Gynecology and Obstetrics
Volume281
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Fingerprint

Adenocarcinoma
Monoclonal Antibodies
Neoplasms
Avidin
Antibodies
Biotin
Hysterectomy
Formaldehyde

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. / Han, Chih Ping; Kok., Lai Fong; Lee, Ming Yung; Wu, Tina S.; Ruan, Alexandra; Cheng, Ya Wen; Wang, Po Hui; Koo, Chiew Loon; Tyan, Yeu Sheng.

In: Archives of Gynecology and Obstetrics, Vol. 281, No. 2, 02.2010, p. 317-323.

Research output: Contribution to journalArticle

Han, Chih Ping ; Kok., Lai Fong ; Lee, Ming Yung ; Wu, Tina S. ; Ruan, Alexandra ; Cheng, Ya Wen ; Wang, Po Hui ; Koo, Chiew Loon ; Tyan, Yeu Sheng. / Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. In: Archives of Gynecology and Obstetrics. 2010 ; Vol. 281, No. 2. pp. 317-323.
@article{e62ffdf905124006adf7f3a92d5c634d,
title = "Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study",
abstract = "Background The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor's site of origin. Some panels of antibodies help to distinguish primary ECA from EMA. However, unexpected expressions of those markers often exist, which causes this diagnostic dilemma to be still unresolved. In this study, we investigate Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) to evaluate their potential use in distinguishing between these two gynecologic malignancies. Methods A tissue microarray was constructed using paraYnembedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. Utilizing the avidin-biotin (ABC) technique, tissue array sections were immunostained with the Wve aforementioned commercially available antibodies. Results Immunohistochemical (IHC) expressions of p53, TTF1, CK7, CK20, and CK34βE12 were all nonsignificant (P > 0.05) in frequency diVerences between the immunostaining results (positive vs. negative) in tumors from both the two primary adenocarcinomas (ECA vs. EMA). Conclusion It is still uncertain which markers or panels would be the most appropriate for making diagnoses; hence, exploration of other useful markers, which make a deWnitive distinction between ECA and EMA merits further studies. This study, however, uncovered that the Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) are of no beneWcial value in distinguishing between primary ECA and EMA.",
author = "Han, {Chih Ping} and Kok., {Lai Fong} and Lee, {Ming Yung} and Wu, {Tina S.} and Alexandra Ruan and Cheng, {Ya Wen} and Wang, {Po Hui} and Koo, {Chiew Loon} and Tyan, {Yeu Sheng}",
year = "2010",
month = "2",
doi = "10.1007/s00404-009-1115-z",
language = "English",
volume = "281",
pages = "317--323",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study

AU - Han, Chih Ping

AU - Kok., Lai Fong

AU - Lee, Ming Yung

AU - Wu, Tina S.

AU - Ruan, Alexandra

AU - Cheng, Ya Wen

AU - Wang, Po Hui

AU - Koo, Chiew Loon

AU - Tyan, Yeu Sheng

PY - 2010/2

Y1 - 2010/2

N2 - Background The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor's site of origin. Some panels of antibodies help to distinguish primary ECA from EMA. However, unexpected expressions of those markers often exist, which causes this diagnostic dilemma to be still unresolved. In this study, we investigate Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) to evaluate their potential use in distinguishing between these two gynecologic malignancies. Methods A tissue microarray was constructed using paraYnembedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. Utilizing the avidin-biotin (ABC) technique, tissue array sections were immunostained with the Wve aforementioned commercially available antibodies. Results Immunohistochemical (IHC) expressions of p53, TTF1, CK7, CK20, and CK34βE12 were all nonsignificant (P > 0.05) in frequency diVerences between the immunostaining results (positive vs. negative) in tumors from both the two primary adenocarcinomas (ECA vs. EMA). Conclusion It is still uncertain which markers or panels would be the most appropriate for making diagnoses; hence, exploration of other useful markers, which make a deWnitive distinction between ECA and EMA merits further studies. This study, however, uncovered that the Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) are of no beneWcial value in distinguishing between primary ECA and EMA.

AB - Background The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor's site of origin. Some panels of antibodies help to distinguish primary ECA from EMA. However, unexpected expressions of those markers often exist, which causes this diagnostic dilemma to be still unresolved. In this study, we investigate Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) to evaluate their potential use in distinguishing between these two gynecologic malignancies. Methods A tissue microarray was constructed using paraYnembedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. Utilizing the avidin-biotin (ABC) technique, tissue array sections were immunostained with the Wve aforementioned commercially available antibodies. Results Immunohistochemical (IHC) expressions of p53, TTF1, CK7, CK20, and CK34βE12 were all nonsignificant (P > 0.05) in frequency diVerences between the immunostaining results (positive vs. negative) in tumors from both the two primary adenocarcinomas (ECA vs. EMA). Conclusion It is still uncertain which markers or panels would be the most appropriate for making diagnoses; hence, exploration of other useful markers, which make a deWnitive distinction between ECA and EMA merits further studies. This study, however, uncovered that the Wve commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) are of no beneWcial value in distinguishing between primary ECA and EMA.

UR - http://www.scopus.com/inward/record.url?scp=77950359257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950359257&partnerID=8YFLogxK

U2 - 10.1007/s00404-009-1115-z

DO - 10.1007/s00404-009-1115-z

M3 - Article

C2 - 19444461

AN - SCOPUS:77950359257

VL - 281

SP - 317

EP - 323

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 2

ER -